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1. Introduction 
Scholz’s disease or metachromatic leukodystrophy (MLD) is a lysosomal storage disease 
caused by a deficiency in arylsulfatase A (ARSA: EC 3.1.6.8). This enzyme is responsible for 
the degradation of sulfatides commonly called cerebroside-3-sulfate or 3-O 
sulfogalactosylceramide in galactocerebroside and sulfate. The success of hydrolysis of these 
sphingolipids by ARSA necessarily depends on the presence of saposine B forms a complex 
with the substrate. The pathological accumulation of sulfatides in the nervous system 
(myelin, neurons and glial cells) results most often neurological, mental retardation, nervous 
disorders, blindness. The metachromatic granules accumulated in the central nervous 
system and peripheral compounds are highly toxic. These are at high levels in the urine of 
patients affected by the MLD. Arylsulfatase A activity is collapsed in these patients. 
Unfortunately, the value of enzyme activity is not a predictor of clinical severity of the 
neuropathology. In contrast, the study of the gene that codes for the ARSA is seen as a way 
to diagnose the simplest and most reliable of the disease to avoid misdiagnosis due to the 
presence of pseudodeficit. The conventional therapeutic approaches are essentially 
symptomatic. They were made in order to restore the enzyme activity of arylsulfatase A and 
prevent the progression of the pathological accumulation of sulfatides and consequently 
reduce morbidity associated with MLD. 
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The sphingolipidoses represent all lysosomal storage diseases that is characterized by the 
accumulation of sphingolipids essentially in lysosomes and that their etiopathogenic 
mechanisms are released (Murray et al., 1996). 
These disorders are genetically caused by a deficiency of lysosomal protein or its activator 
(Beaudet et al., 2001). These proteins are involved in the catabolism of sphingolipids, which 
are complex lipid molecules. They derive from a common structural element, the 
ceramide. Ceramides are formed by the association of an amino alcohol to 18 carbons in a 
sphingosine called fatty long-chain acid which are saturated or not, and hydroxylated or 
not. Sphingosine has a center formed from a hydrophilic primary alcohol, the amine, a 
secondary alcohol function, and a pole with a hydrophobic acyl chain with a double 
bond. The structure of various sphingolipids nervous system corresponds to various 
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substitutions fixed on the hydroxyl group of carbon 1 of the sphingosine by ester or 
glycosidic bond (Métais et al, 1980a). 
These sulfatide which are the major components of the myelin have the structure of 
cerebroside sulfate, the sulfo-galactosylceramide whose 3-hydroxyl of galactose is esterified 
by sulfuric acid which are the more important in this group (Fig. 1. Structure of sulfatide, 
Cui et al., 2008).  
 
 
 
Fig. 1. Structure of sulfatide 
The sphingolipidoses are classified according to the nature of the enzyme deficiency and 
substrate accumulated (Table1. Classification of the main Sphingolipidosis, Borel et al., 1999) 
 
 
 
 
 
 
Disease Deficient enzyme Accumulated products Symptoms 
Gaucher disease ǃ-Glucosidase Glucosylceramide 
Hepatosplenomegaly, 
Mental retardation, Bone 
pain 
Krabbe disease 
Galactocerebrosyl-
ǃ-galactosidase Galacosylceramide 
Mental retardation, 
Neurodenegeration , 
Decerebration-like 
Fabry disease ǂ-galactosidase  Globotriaosylceramide
Ischemic infarction in 
affected organs, 
Angiokeratomas 
hypohidrosis, Mental 
retardation 
Tay-Sachs 
disease 
Hexosaminidase A GM2-ganglioside 
Neurodegeneration, 
Developmental disability, 
kidney and skin disorders 
Metachromatic 
leukodystrophy
Arylsulfatase A Sulfatide 
Demyelinisation 
in CNS and PNS, Mental 
retardation 
 
Niemann-Pick 
disease 
Sphingomyelinase Sphingomyelin 
Hepatosplenomegaly, 
Mental retardation 
 
 
Table 1. Classification of the main Sphingolipidosis 
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A great clinical and biological heterogeneity characterizes these metabolic diseases. Various 
Clinical forms, severe or moderate, may correspond to same enzyme deficiency, which 
explains the diagnosis difficulty of these disorders (Von Figura et al., 2001). 
 
 
 
Fig. 2. Catabolism of sphingolipids and enzyme deficiencies responsible for 
sphingolipidoses. 1 : gangliosido-ǃ- galactosidase ; 2 : ǃ-hexosaminidase A ; 3 : ǃ-
hexosaminidase A et B ; 4 : neuraminidase ; 5 : ǂ-galactosidase A ; 6 : lactosyl-ceramide-ǃ-
galactosidase ; 7 : cerebroside-ǃ-glucosidase ; 8 : sphingomyelinase ; 9 : cerebroside-ǃ-
galactosidase ; 10 : arylsulfatase A ; 11 : ceramidase. 
Metachromatic leukodystrophy (MLD) is a sphingolipidosis which corresponds to the loss 
of myelin in areas normally myelinated ago (Maria et al., 2003). The MLD or Scholz’s disease 
was discovered by Scholz Greenfield in 1925. This is a recessive autosomal disease. This 
encephalopathy, which results from a deficiency of arylsulfatase A (ARSA, EC 3.1.6.8) is 
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involved in sulfatides hydrolysis to galactosyl-cerebroside and sulfate (Fig.2. Catabolism 
of sphingolipids and enzyme deficiencies responsible for sphingolipidoses, Métais et al, 
1980b). 
The accumulation of these toxic metabolites is the origin of lesions in the white matter in 
central and peripheral nervous system (Logowska et al., 2005). Some Rare cases of MLD are 
due to saposin B deficiency: sphingolipid activator protein B (Sap-B) (Deconinck et al., 2008).  
The existence of arylsulfatase A pseudodeficiency in 7 to 15% of the population is causing 
by a collapsed ARSA activity without clinical signs (Bognar et al., 2002).The incidence of the 
MLD varies from 1 / 40 000 to 1 / 100 000. For Habbanites Jews, it’s estimated at 1.3 percent 
(Kolodny & Fluharty, 1995a). 
2. Clinical presentation 
Clinically, three phenotypes were distinguished: Late infantile, juvenile and adult 
form. These phenotypes vary according to the absence or presence of neurological 
manifestations and their progression degree. The late infantile form is the most severe and 
frequent form, accounting for 60%. The symptoms appear before 4th age. The motor 
regression starts at the age of walking. Intellectual abilities are preserved until installing a 
state of terminal decerebration with pyramido-extrapyramidal syndrome. 
Reflexes tendon’s abolition is found early and reflects the association of peripheral 
neurological signs, the death often occurs 2-4 years after initial diagnosis (Kolodny & 
Fluharty, 1995b). The juvenile form symptoms (20 to 30% of cases) occurs between 4 and 16 
years manifested most often by behavioral and walking disorders. It is characterized by a 
decreases in intellectual performance, emotional difficulties and language disorders. The 
motor regression is progressive. The majority of patients die at the age of 10 years, but 
survival is sometimes possible to more than 20 years (Maire et al., 2007). On the adult 
form (10 to 20% of cases) the symptoms occurs between 16 and 60 years, with a variable 
speed of evolution. The patient has generally a change of personality, behavior disorders, 
and then a decrease in intellectual and professional performance, memory loss and 
dementia (Bauman, 2002; Turpin, 1994a).  
3. Pathophysiology of MLD 
The sulfatides accumulate in the central and peripheral nervous systems are highly 
toxic compounds which found in high concentrations in the urine of patients affected by 
MLD (Whitufield et al., 2001). It was demonstrated that metachromatic granules accumulate 
in many organs: gall bladder, liver, pancreas, ovaries and lymph nodes.  
The renal tubular epithelium is usually affected, they can be also found in the eye, in the 
dental pulp. Microscopically the demyelination is diffuse. It mainly affects the cerebral 
hemispheres, fibrillary gliosis is important. The metachromatic granules are alcianophiles, 
they can be extracellular and can also be situated on glial cells or macrophages. The deposit 
can reach 20 to 30 microns in diameter. However, these granules are more numerous in most 
affected white matter regions, but the gray matter is normal. The Peripheral nerve is always 
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affected by observing segmental demyelination and metachromatic substance deposits in 
Schwann cells, are showed in electron microscopy. (Turpin et al., 1994b) 
4. The cerebroside-sulfatase (CSS) or cerebroside 3-sulfatase 
or arylsulfatase A (ARSA) 
The arylsulfatase A is belongs to the sulfatases family. These sulfatases ensure the hydrolysis 
of esters sulfate such that O-sulfates and N-sulfates with different specific substrates. 
In humans, there are 17 small sulfatases, 500 to 800 amino acids; ARSA protein has 
507 amino acids. These enzymes are characterized by structural homology to the entire 
sequence, particularly in the N-terminal region. They have also a similar active site. The 
catalytic site of ARSA is located in a positively charge pocket and it acts as a ligand 
involving magnesium. The active site of this enzyme contains ǂ helices that surround 
a large ǃ sheet. The dissulfure bridge (SS) is located between the aspartate (Asp335) and 
arginine (Arg370) residue. The sulfatases require posttranslational oxidation affecting cysteine 
leading to the formation of aldehyde which will facilitate theproduction of formyl glycine 
(FGL).  Diez  Roux  and Ballabio showed that FGL is essential for the catalytic activity of the 
enzyme. (Cesani, 2009a; Diez-Roux & Ballabio, 2005a; Schestag, 2002). 
The quaternary structure is pH-dependent; at neutral pH, the structure is dimeric, where 
as at lysosomal pH (acidic) homo-octameric form is predominant which formed by 
four dimmers.  
The ARSA structure analysis is important to understanding the mutations and the genotype 
phenotype correlation studies. The ARSA is encoded by a gene located on 22q13.  
Stein et al. have been cloned and sequenced the human ARSA gene. It spans 3,2 Kb genomic 
DNA and is separated into eight exons ranging in size from 116 to 362 bp. The ARSA gene is 
transcribed into three mRNA species of different sizes (2.1, 3.7 and 4.8 kb) (Lukatela et al., 
1998). 
5. Phenotype/genotype relationship 
Since the identification of ARSA gene, more than 118 mutations have been described so 
far. Many point mutations (missense and non sense), many substitutions, splicing 
mutations, and some deletions and insertions have been reported (Cesani, 2009b). However, 
most common mutations in the general population: the IVS2 + 1G> A mutation which 
associated with the late infantile form, the P426L mutation is frequently associated with the 
juvenile form, I179S mutation is associated with adult form and pseudodeficiency: N350 and 
1524 +95 A → G (poly A-) (Clouter-Mackie & Gagnier, 2003). The distinction between the 
three phenotypes of MLD in the literature (late infantile, juvenile and adult form) posed a 
major problem for clinicians because they had just the age of clinical signs onset to typing 
different MLD forms. Recently, according to the study of Biffi et al., it is possible to 
establish phenotype-genotype relationship.  
These authors proposed a classification of clinical forms of MLD based on the genotype, 
residual enzyme activity and the study of the expression of mutated proteins (Biffi et al., 
2008). 
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6. Biological diagnosis 
Various explorations are necessary in any acquired encephalopathy case resulting 
psychomotor regression. The biochemical diagnosis includes the following studies: 
6.1 Urinary sulfatide analysis 
The study of urinary excretion of sulfatides is possible by thin layer chromatography or 
spectrometry mass (Colsch et al., 2008). 
6.2 Enzymatic study  
The Confirmatory diagnosis is based on the demonstration of the ARSA deficiency. The 
determination of enzyme activity can be made on leukocytes circulating blood of sick 
patients, or skin fibroblasts in culture. The measurement of enzyme activity is possible by 
colorimetric method using a Synthetic substrate: paranitrocathechol sulfate (Dubois et al., 
1975). However, the collapsed enzyme activity is not a predictor factor of MLD clinical 
severity. The study of heterozygotes subjects by measurement of enzyme activity is limited 
because there is an overlap between the values of ARSA activity in normal and 
heterozygotes subjects. The multiple sulfatase deficiency (MSD) leds to many problems in 
the result’s interpretation (Diez-Roux & Ballabio, 2005b). In some clinically healthy subjects 
or suffering from neurological diseases other than MLD, the value of enzyme activity 
observed may be low, for the existence of the pseudodefeciency alleles. These alleles 
represent 7-15% of alleles in the general population.  Two mutations described are 
responsible for that: N350 (PD1) 1524 95 A → G or poly A-(PD2). ARSA pseudodeficiency 
must be recognized to avoid misdiagnosis like for prenatal diagnosis in families where 
coexists one allele of MLD (Polten et al., 1991a). 
6.3 Molecular diagnosis 
Molecular diagnosis of MLD is the more accurate and uses samples more stable than those 
used for determining enzyme activity. This diagnosis can contribute to the identification 
of common mutations in the ARSA gene especially in the heterozygous subjects (Polten et 
al., 1991b). Genomic DNA was extracted from leukocytes, and was amplified by PCR  
(polymerase chain reaction) using oligonucleotide primers already described. Patients or 
their parents were screened for the presence of the most frequent MLD causal mutation by 
restriction endonuclease digestion and sequencing. 
6.4 Prenatal diagnosis 
Prenatal diagnosis is the best way to put heterozygous couple, especially in a who had 
couple already an affected child (index case). Two methods are proposed, the amniocentesis 
and chorionic amniocentesis. The chorionic villous biopsy is performed upon 8th or 9th week 
of pregnancy. This technique provides rapid results (maximum 3 days). Amniocentesis is 
achievable in the 14th week of gestation. Diagnostic confirmation is always performed 
after measurement of enzyme activity in amniotic cells crop, which will delay the results 3-4 
weeks. Currently, the identification of fetal genotype and predicting the type of the disease 
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even in the absence of family history has become easier with the use of molecular 
technologies (Maire, 2004).  
7. Treatment 
7.1 Bone Marrow Transplant (BMT)  
The BMT reconstitute the hematopoietic system of patient with stem cells from a healthy 
donor. Several patients with infantile and juvenile form of MLD received BMT. No signs of 
regression have been reported, with the exception of a child who had a neurological 
improvement post-BMT, but the BMT in patients with adult form was very beneficial.  
Improvement of neurological symptoms associated with a normalization of their ARSA 
activities and their sulfatide rate was noted. The post-BMT survival in patients suffering 
from adult form is estimated at 77% (Krivit et al., 2001). 
7.2 Enzyme replacement  
Enzymatic Therapy is to administer to the patient the active deficient enzyme which is 
responsible for his illness. Recently in Denmark, a test of enzyme replacement therapy 
was offered to children with the late infantile form. The clinical trial includes the study of 
safety and tolerance in the first phase. Patients are then followed in the second phase to 
study the dose-response. The enzyme which used in the test is similar to the human 
enzyme. To assess the Metazym ® effect, the nervous system of patients has been 
evaluated at the beginning of therapy and after 6 to 12 months. These evaluations 
include MRI, cognitive tests, measurements of nerve conduction and motor function (Dali 
& Lund, 2009). 
7.3 Substrate-reduction therapy with warfarin 
The warfarin is an anticoagulant and an antagonist of vitamin K, The first Warfarin 
studies in mice showed that this compound inhibits the synthesis of sphingolipids leading 
to sulfatide reducing (Crowther et al., 2009). 
7.4 Gene therapy 
Gene therapy involves introducing into the body patient's a normal version of the defective 
gene which responsible of his illness. To date, several approaches are tested in animal 
models (Consiglio et al., 2000). 
8. Conclusion 
Metachromatic leukodystrophy is a sphingolipidosis caused by arylsulfatase A deficiency. 
This enzyme catalyses the first degradation step of the sulfatide. 
Several mutations were identified in the ARSA gene which abolish the catalytic activity and 
may reduce the ARSA stability. Thus, the study of the ARSA gene three-dimensional 
structure associated with the search for the mutations responsible of MLD could establish 
phenotype-genotype relationship. 
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